Lifestyle modification counseling of patients with dyslipidemias by pharmacists and other health professionals

Journal of the American Pharmacists Association

Volumn 45, Issue 6, 2005, Pages 709-713

  Lenz, Thomas L ^a   Stading, Julie A ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dyslipidemias; Lifestyle modifications; Patient counseling

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; DYSLIPIDEMIA; EXERCISE; FOLLOW UP; HEALTH PRACTITIONER; HEALTH SURVEY; HOSPITAL; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL PRACTICE; NURSE; PATIENT COUNSELING; PHARMACIST; PHARMACY; PHYSICIAN; PRESCRIPTION; PREVALENCE; REVIEW; UNITED STATES; ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; DIRECTIVE COUNSELING; FEMALE; LIFESTYLE; MALE; MIDDLE AGED; PATIENT EDUCATION; PHYSICIAN ATTITUDE; QUESTIONNAIRE; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; COMMUNITY PHARMACY SERVICES; CROSS-SECTIONAL STUDIES; DIRECTIVE COUNSELING; DYSLIPIDEMIAS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PATIENT EDUCATION; PHARMACISTS; PHYSICIAN'S ROLE; QUESTIONNAIRES;

EID: 33644795865     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434505774909661     Document Type: Article

References (7)

1. American Heart Association. Heart disease and stroke statistics-2003 update. Dallas, Tex.: American Heart Association; 2003.
2. National Institutes of Health, National Heart Lung and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) on the detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda, Md.: National Institutes of Health; 2002. NIH Publication 02-5215.
3. Grundy SM, Cleeman JI, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
4. Geber J, Parra D, Beckey NP, Korman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy. 2002;22:738-47.
5. Lopez LM. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. Am J Health Syst Pharm. 2002;59:1173-82.
6. Ross TT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management. The study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162:1149-55.
7. McKenney JM, Bradberry JC, Talbert RL, et al. National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statin therapy, and pharmacists' services. J Am Pharm Assoc. 2004;44:562-8.